Beschreibung

Bioavailability challenges for resveratrol and formulation strategies to improve its therapeutic efficacy in MASLD are reviewed.

Figure 7

Diagram

Source Paper

Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?

International journal of molecular sciences (2024)

PMID: 38612556

DOI: 10.3390/ijms25073746

Cite This Figure

![Figure 7: Bioavailability challenges for resveratrol and formulation strategies to improve its therapeutic efficacy in MASLD are reviewed.]()

> Source: Kamila Kasprzak-Drozd et al. "Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Diseas." *International journal of molecular sciences*, 2024. PMID: [38612556](https://pubmed.ncbi.nlm.nih.gov/38612556/)

<figure>
  <img src="" alt="Bioavailability challenges for resveratrol and formulation strategies to improve its therapeutic efficacy in MASLD are reviewed." />
  <figcaption>Figure 7. Bioavailability challenges for resveratrol and formulation strategies to improve its therapeutic efficacy in MASLD are reviewed.<br>  Source: Kamila Kasprzak-Drozd et al. "Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Diseas." <em>International journal of molecular sciences</em>, 2024. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/38612556/">38612556</a></figcaption>
</figure>

Beschreibung

Figure 7

Source Paper

Cite This Figure

Verwandte Evidenz